Triple reuptake inhibitors: a premise and promise.
On the horizon there is a new class of psychoactive medications which work by inhibiting the neuronal reuptake of serotonin, norepinephrine, and dopamine. There are multiple potential indications for these drugs. Research suggests that they may have a role in treating depressive disorders, and it is plausible they may have potential efficacy in obesity, addiction, and pain syndromes. The current review describes some of the molecules in development presently and explores the research relevant to possible clinical uses for this class of medications.
Marks
David M
DM
Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, USA.
Pae
Chi-Un
CU
Patkar
Ashwin A
AA